Risk of bias assessment for eligible randomized controlled trials. by Junyin Pan (20700411)

Subjects:

Summary of studies identified in the literature search, including studies excluded from the analysis and reasons for exclusion. by Junyin Pan (20700411)

Subjects:

The flow chart of study selection process. by Junyin Pan (20700411)

Subjects:

Data extracted from included studies for the systematic review and meta-analysis. by Junyin Pan (20700411)

Subjects:

Specifications and outcomes of clinical trial studies included in the meta-analysis. by Junyin Pan (20700411)

Subjects:

Effect of MF (2 MT, 50 Hz) on VEGFR expression and activation. by Simona Delle Monache (402973)

“…<p>Protein of equal quantity was separated by 8% SDS-page and electroblotted on to a PVDF membrane. Representative blots show effects exerted by MF (2 mT, 50 Hz) on VEGFR2 total expression and phosphorylation after 1 h, 6 h and 12 h of exposure A). …”

Numbers of all fractures, arranged in order of decreasing mean age and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age. by Camilla Bergh (9904522)

“…<p>Numbers of all fractures, arranged in order of decreasing mean age and with proportion of each of the fracture types in patients over 50, 65, and 75 years of age.…”

Respiratory pattern. by Yoichiro Kitajima (4319455)

Subjects:

Protocols. by Yoichiro Kitajima (4319455)

Subjects:

BH3 Peptides induces a decrease in mitochondrial membrane potential but does not engage the Permeability Transition Pore. by Emelyn H. Shroff (163459)

Compounds decrease polyQ toxicity in a <i>pqe-1</i> independent manner in aged animals. by Cindy Voisine (30589)

Pretreatment of β-cells with recombinant CXCL12 improves viability and induces a decrease in PARP-1 activity. by Nevena Grdović (394542)

Effects of protein-bound uremic solutes on total glutathione level. by Takeo Edamatsu (4885138)

A picture of service-bed compartment of the gamma spectrometry vehicle used in the experiment. by Antanas Bukartas (10023785)

Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC₅₀ concentration of fenretinide during different time points (24–48–72 hours). …”

Decreased IFNγ production by Ly49H⁺ NK cells in A/J mice. by Nassima Fodil (669326)

Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. by Mariam El-Ashmawy (678638)

“…Data analyzed and calculated using Open Comet software [tail moment = tail length x tail DNA percentage]. Mean ± SEM of >50 cells per condition, *p<0.05 using t-test (compared to 3 Gy DMSO). …”

Living cells are decreased in the PDL on the pressure side of a Pn−/− molar tooth subjected to experimental tooth movement. by Hideyuki Tanabe (243557)

M344 decreases orthotopic pancreatic tumor growth when used as a treatment alone or in combination with gemcitabine. by Shelby M. Knoche (13833807)

Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

“…<i>n</i> = 3 mice per genotype. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.001 versus Scrib WT CL. Scale bars: A,B,D,E: 2 μm. J,K: 50 μm.</p>…”